C-BQH0Abliva
orphan drugs, mitochondrial disease
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BQH0
C-BQH0C-BQH0orphan drugs, mitochondrial disease
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Abliva orphan drugs, mitochondrial disease
Abliva describes itself as delivering mitochondrial health and developing orphan drugs. Its in-house R&D capabilities have produced a portfolio with mechanisms of action suitable for a range of primary mitochondrial disease types. The site lists KL1333, NV354, early programs, and the FALCON Study.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Abliva — Translational · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic